Syros Pharmaceuticals said it plans to wind down its operations, according to a Securities and Exchange Commission filing. The Cambridge, Mass., company said it would proceed with a voluntary ...

Syros Pharmaceuticals (SYRS) announced that its Board of Directors has approved and the company intends to proceed with the voluntary delisting ...

EST Syros Pharmaceuticals (SYRS) trading halted, news pendingDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) has been given a consensus rating of “Hold” by the five research ...

Looking to buy an urban family diesel car under Rs 15 lakh? Here’s why the Kia Syros should be on top of your list.

Syros gets two engine options – a 1.0-litre, 3-cylinder, turbo-petrol which puts out 120hp of power and 172Nm torque. It ...

The 1930s-set, six-part drama series about a woman trying to break free from tradition adapts one of the great Greek novels ...

Discover the top 5 cars equipped with ADAS Level 2 technology, offering enhanced safety and convenience features. From Kia ...

Kia has already seen over 20,000 interested buyers who have booked themselves brand-new Syros! Here is a look at the premium ...

The Kia Syros is the latest addition to the lineup of cars in India and comes at a starting price of Rs 9 lakh (ex-showroom).

Kia Syros introduces a range of innovative technologies, including a segment-first Over-the-Air (OTA) software update system.

Syros Pharmaceuticals, which said in November it would cut most of its workforce, said on Friday it will wind down operations. The company's stock dropped 45% to 8 cents in after-hours trading.